About the Study:
There are few treatments approved for the acute treatment of migraines in adolescents and only one treatment is approved for children aged 6 – 11 years old. Rochester Clinical Research is conducting a research study to test the safety, efficacy, and tolerability of Lasmiditan for acute migraines in children. Lasmiditan, the study medicine, works by blocking the pain pathway from the nerves in your head.
The study will last approximately 4 months with 3 visits to our office. Compensation is available for time and travel for those who qualify. Study-related care is available to participants at no cost and health insurance is not required nor needed.
- Patient is between the ages of 6-18 years old
- Patient has a history of 2-8 migraines per month, in the last 3 months prior to screening
- Patient must be able to swallow a tablet
- Please note, other conditions may apply.